UFP Technologies Q4 sales slightly miss estimates

UFP Technologies

24/02/2026 21:48

Overview

Medical device maker's 2025 sales grew 19.5%, driven by 23.2% rise in medical sales

Q4 sales slightly missed analyst expectations

Company faced $6.3 mln labor inefficiencies at AJR facility, expects continued progress

Outlook

Company plans to add a new facility in Dominican Republic in Q2 2026

UFP Technologies expects significant growth in Safe Patient Handling market in 2026

Company remains bullish about future due to new talent and contract extensions

Result Drivers

MEDICAL SALES GROWTH - Co's 2025 revenue growth was driven by a 23.2% increase in medical sales

LABOR INEFFICIENCIES - Co absorbed $6.3 mln in labor-related inefficiencies at AJR facility, impacting FY earnings

Company press release: ID:nGNX2tGqQV

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Slight Miss*
$148.92 mln
$149.07 mln (4 Analysts)
Q4 EPS
$2.28
Q4 Net Income
$17.57 mln
Q4 Gross Profit
$41.97 mln
Q4 Operating Income
$21.50 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for UFP Technologies Inc is $329.50, about 36.3% above its February 23 closing price of $241.79

The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 20 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)